A28 Therapeutics and GATC Health Announce Comprehensive AI-Powered Analysis, Predicting Efficacy, Safety, and Potential Off-Target Effects of A28’s AT-101 Cancer Drug Candidate

Posted on by

The analysis provides detailed insights to optimize clinical trial strategy, accelerate development, and de-risk decision-making. SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ — A28 Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel platform technology for the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.